Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURVEYOR
NCT05358821Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of dalzanemdor in Huntington disease (HD) (3 arms), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Difference in Huntington's Disease Cognitive Assessment Battery (HD-CAB) Composite Score Between Participants With HD vs HP at Baseline. Started May 2022; status: completed.
02
Drugs
dalzanemdor
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT05358821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358821.